Vimarsana
Biggest News Aggregation in the World

Continuous Treatment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Continuous Treatment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Continuous Treatment Today - Breaking & Trending Today

Injected antipsychotics may be more effective against schizophrenia than pills - Vimarsana News

Injected antipsychotics may be more effective against schizophrenia than pills

For people with schizophrenia hospitalized after a psychotic episode, getting a long-acting antipsychotic injection works far better than pills to keep them from returning to hospital care.

Source: yahoo.com
Community rallies around Lake Oswego woman with rare breast cancer - Vimarsana News

Community rallies around Lake Oswego woman with rare breast cancer

The Lake Oswego community is rallying around one of their own, as she faces a stage four diagnosis of a rare breast cancer and a denial from her insurance to cover a potentially life-saving procedure.

Source: yahoo.com
Follicular Lymphoma: Patient Monitoring and Maintenance Therapy - Vimarsana News

Follicular Lymphoma: Patient Monitoring and Maintenance Therapy

Before closing out their discussion on first-line management of follicular lymphoma, experts consider the importance of patient monitoring and discuss the diminished role of maintenance therapy.

New clinical and real-world data for Roche's Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss - Vimarsana News

New clinical and real-world data for Roche's Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss

Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema Real-world data reinforce that...

New Clinical and Real-World Data for Genentech's Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss - Vimarsana News

New Clinical and Real-World Data for Genentech's Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss

‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) –‒ Real-world data reinforce that first-line Vabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for p...